Skip to main content

Drug Interactions between chikungunya vaccine, live (cvx 317) and Hyftor

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sirolimus topical chikungunya vaccine, live (cvx 317)

Applies to: Hyftor (sirolimus topical) and chikungunya vaccine, live (cvx 317)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Sirolimus may be systemically absorbed following topical administration and in some patients may have systemic immunosuppressive effects. Theoretically, administration of vaccines or oncolytic immunotherapy containing live, attenuated virus or bacteria during treatment with topical sirolimus may be associated with a risk of infection due to enhanced replication of virus or bacteria in the presence of diminished immune competence. These patients may also have decreased or suboptimal immunologic response to vaccines or oncolytic immunotherapy. However, no formal studies have been conducted to evaluate the response to vaccination or oncolytic immunotherapy during treatment with topical sirolimus.

MANAGEMENT: Live vaccines and oncolytic immunotherapy such as talimogene laherparepvec and the BCG strain of Mycobacterium bovis should be avoided in patients receiving topical sirolimus. Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with topical sirolimus. Current local immunization guidelines should be consulted for recommendations on waiting periods for treatment with topical sirolimus before and after administration of live, attenuated viral or bacterial vaccines.

References

  1. "Product Information. Hyftor (sirolimus topical)." Nobelpharma America, LLC (2022):

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer